Shandong Weigao Group Medical Polymer Company Limited
1066Company Overview
Shandong Weigao Group Medical Polymer Products Co., Ltd. is mainly engaged in R&D, production and sales of medical device products, orthopedic products, interventional products, pharmaceutical packaging products, blood management products, and operating financing business. As far as management is concerned, the Group is currently divided into six business divisions - medical device products, orthopedic products, interventional products, pharmaceutical packaging products, blood management products and others. Among them, interventional products are manufactured by Elang Medical Devices Holdings Co., Ltd. (“Ailang”). These divisions are divided according to the internal reporting standards of each division of the Group and are regularly reviewed by key operating decision makers (managing directors) to allocate resources to the segment and evaluate its performance. The main businesses of the Group's operating and reportable divisions are as follows: Medical device products - production and sale of clinical care, medical testing, anesthesia and surgery-related products and other consumables Orthopedic products - production and sale of orthopedic products Interventional products - production and sale of oncology and vascular interventional devices Pharmaceutical packaging products - production and sale of pre-filled syringes and syringes Blood management products - production and sale of blood collection, radiation, storage, separation, sterilization and disinfection products Other - Financial leasing and factoring business
Shariah Compliance Benchmarks:
- Business Compliance: Non-Shariah compliant revenue must be less than 5% of total revenue
- Liabilities Compliance: Interest-bearing debt must be less than 33% of market capitalization
This stock does not meet all Shariah compliance criteria according to AAOIFI standards.
Name | Shandong Weigao Group Medical Polymer Company Limited |
Ticker | 1066 |
Main Business | Medical Instruments & Supplies |
Type | Common Stock |
Industry | Medical Instruments & Supplies |
Country | HK |
Market Cap | $4.46 B |
Shariah Analysis Breakdown
Revenue Segment | Value ($M) | Non-Compliant ($M) | Reason |
---|---|---|---|
Clinical care | $4,726.6 | $0.0 | - |
Pharma packaging products | $2,105.4 | $0.0 | - |
Blood management | $1,098.0 | $0.0 | - |
Medical testing | $325.7 | $0.0 | - |
Anesthesia and surgical related products | $615.6 | $0.0 | - |
Orthopaedic products | $1,830.4 | $0.0 | - |
Interventional products | $1,938.2 | $0.0 | - |
Other consumables | $979.1 | $0.0 | - |
Other income | $323.2 | $180.3 | Interest income |
Other gains and losses | $121.6 | $19.6 | Gain from changes in fair value of financial instruments measured at FVTPL |
Total | $14,063.8 | $199.8 | 1.42% (passed) |
Liability Item | Value ($M) | % of Market Cap |
---|---|---|
bank loans and overdrafts | $357,142,857.1 | 8.01% |
long term bank loan | $70,012,605.0 | 1.57% |
convertible notes and bonds | $139,413,165.3 | 3.13% |
Total Interest-Bearing Debt | $566,568,627.5 | 12.71% |
Market Capitalization | $4,458,679,487.2 | 100.00% |
Compliance Status | Threshold: 33% | passed |